<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442637</url>
  </required_header>
  <id_info>
    <org_study_id>CAIRO3</org_study_id>
    <nct_id>NCT00442637</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma</brief_title>
  <acronym>CAIRO3</acronym>
  <official_title>Maintenance Treatment With Capecitabine and Bevacizumab Versus Observation After Induction Treatment With Chemotherapy and Bevacizumab as First-line Treatment in Patients With Advanced Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Koningin Wilhelmina Fonds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dutch Colorectal Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal duration of systemic treatment in patients with advanced colorectal cancer is&#xD;
      unknown.&#xD;
&#xD;
      In this study the effects of bevacizumab and low-dose continuous chemotherapy with&#xD;
      capecitabine is investigated in patients who have responded to 6 courses of oxaliplatin,&#xD;
      capecitabine and bevacizumab (&quot;induction treatment&quot;, at standard doses). This treatment is&#xD;
      continued until progression or severe toxicity. This regimen is compared to the effects a&#xD;
      observation without treatment after the induction treatment.&#xD;
&#xD;
      In case of disease progression, induction treatment will be reintroduced.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard 1st-line treatment for patients with advanced colorectal cancer currently consists&#xD;
      of chemotherapy plus bevacizumab. With this approach the median overall survival is&#xD;
      approximately 20 months, and progression-free survival in first-line approximately 9-11&#xD;
      months. The optimal duration of treatment is unknown. Current data suggest that the efficacy&#xD;
      of bevacizumab is dependent on concomitant use of chemotherapy. However, oxaliplatin almost&#xD;
      invariably gives rise to neuropathy after 6-8 cycles. Prolonged use of capecitabine is&#xD;
      associated with e.g. hand-foot syndrome. Lastly, the prolonged use of these agents is&#xD;
      associated with considerable costs.&#xD;
&#xD;
      Evidence, mainly preclinical, suggests that continuous dosing metronomic chemotherapy may be&#xD;
      more efficacious than interval-chemotherapy given at MTD. In this study the concept of&#xD;
      metronomic chemotherapy is explored by administering a continuous daily instead of the usual&#xD;
      2 weeks-on/1 week-off oral dosing regimen of low-dose capecitabine plus bevacizumab as&#xD;
      maintenance therapy after induction combination chemotherapy given at MTD plus bevacizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival after re-introduction of MTD chemotherapy and bevacizumab (PFS2)</measure>
    <time_frame>study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival between observation versus maintenance therapy (PFS1)</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate during re-introduction of MTD chemotherapy and bevacizumab</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational research</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">635</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine plus bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine + bevacizumab</intervention_name>
    <description>Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation</intervention_name>
    <description>observation after induction treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Before the start of induction therapy:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological proof of colorectal cancer (in case of a single metastasis, histological&#xD;
             or cytological proof of this lesion should be obtained);&#xD;
&#xD;
          -  Distant metastases (patients with only local recurrence are not eligible);&#xD;
&#xD;
          -  Unidimensionally measurable disease (&gt; 1 cm on spiral CT scan or &gt; 2 cm on chest&#xD;
             X-ray; liver ultrasound is not allowed). Serum CEA may not be used as a parameter for&#xD;
             disease evaluation;&#xD;
&#xD;
          -  In case of previous radiotherapy, at least one measurable lesion should be located&#xD;
             outside the irradiated field.&#xD;
&#xD;
          -  Ongoing or planned first line treatment with 6 cycles of Xeloda, Eloxatin, and&#xD;
             Avastin.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Prior adjuvant treatment for stage II/III colorectal cancer ending within 6 months&#xD;
             before the start of induction treatment&#xD;
&#xD;
          -  Any prior adjuvant treatment after resection of distant metastases&#xD;
&#xD;
          -  Previous systemic treatment for advanced disease&#xD;
&#xD;
        At randomisation:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  WHO performance status 0-1 (Karnofsky PS &gt; 70%);&#xD;
&#xD;
          -  Disease evaluation with proven SD, PR or CR according to RECIST after 6 cycles of MTD&#xD;
             chemotherapy performed in week 3-4 of the 6th cycle induction therapy, and&#xD;
             randomisation performed in week 3-5 of the 6th cycle (see time table);&#xD;
&#xD;
          -  Laboratory values obtained ≤ 2 weeks prior to randomisation: adequate bone marrow&#xD;
             function (Hb &gt; 6.0 mmol/L, absolute neutrophil count &gt; 1.5 x 109/L, platelets &gt; 100 x&#xD;
             109/L), renal function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft&#xD;
             formula, &gt; 30 ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases&#xD;
             ≤ 3 x ULN without presence of liver metastases or ≤ 5x ULN with presence of liver&#xD;
             metastases);&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks;&#xD;
&#xD;
          -  Age &gt;= 18 yrs;&#xD;
&#xD;
          -  Negative pregnancy test in women with childbearing potential;&#xD;
&#xD;
          -  Expected adequacy of follow-up;&#xD;
&#xD;
          -  Institutional Review Board approval;&#xD;
&#xD;
          -  Written informed consent Exclusion criteria&#xD;
&#xD;
          -  History or clinical signs/symptoms of CNS metastases;&#xD;
&#xD;
          -  History of a second malignancy ≤ 5 years with the exception of adequately treated&#xD;
             carcinoma of cervix or basal/squamous cell carcinoma of skin;&#xD;
&#xD;
          -  Previous intolerance of XelodaR, EloxatinR, and/or AvastinR for which any of these&#xD;
             drugs have been permanently discontinued; patients with previous dose reductions or&#xD;
             delays are eligible; patients with grade 2 neurotoxicity after the 6th cycle are&#xD;
             eligible, and retreatment with EloxatinR after PFS1 should depend on the grade of&#xD;
             neurotoxicity at that moment;&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency;&#xD;
&#xD;
          -  (Planned) radical resection of all metastatic disease;&#xD;
&#xD;
          -  Uncontrolled hypertension, i.e. consistently &gt; 150/100 mmHg;&#xD;
&#xD;
          -  Use of more than 3 antihypertensive drugs;&#xD;
&#xD;
          -  Significant cardiovascular disease &lt; 1 yr before randomisation (symptomatic congestive&#xD;
             heart failure, myocardial ischemia or infarction, unstable angina pectoris, serious&#xD;
             uncontrolled cardiac arrhythmia, arterial thrombosis, cerebrovascular event, pulmonary&#xD;
             embolism);&#xD;
&#xD;
          -  Any of these significant cardiovascular events during previous fluoropyrimidine&#xD;
             therapy;&#xD;
&#xD;
          -  Chronic active infection;&#xD;
&#xD;
          -  Any other concurrent severe or uncontrolled disease preventing the safe administration&#xD;
             of study drugs;&#xD;
&#xD;
          -  Any impairment of gastrointestinal function or -disease that may significantly impair&#xD;
             the absorption of oral drugs (i.e. uncontrolled nausea, vomiting, diarrhoea (defined&#xD;
             as &gt;CTC grade 2), malabsorption syndrome, bowel obstruction, or inability to swallow&#xD;
             tablets);&#xD;
&#xD;
          -  Concomitant treatments: concomitant (or within 4 weeks before randomisation)&#xD;
             administration of any other experimental drug under investigation; concurrent&#xD;
             treatment with any other anti-cancer therapy; full-dose anticoagulation (is allowed if&#xD;
             started during induction therapy);&#xD;
&#xD;
          -  Continuous use of immunosuppressive agents (except the use of corticosteroids as&#xD;
             anti-emetic prophylaxis/treatment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. JA Punt, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam Medical Centre, Amsterdam Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl</url>
    <description>Dutch Colorectal Cancer Group</description>
  </link>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2007</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAIRO3</keyword>
  <keyword>DCCG</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>induction</keyword>
  <keyword>metronomic chemotherapy</keyword>
  <keyword>observation</keyword>
  <keyword>capecitabine</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 22, 2016</submitted>
    <returned>October 13, 2016</returned>
    <submitted>October 9, 2017</submitted>
    <returned>July 20, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

